Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Attention Deficit Disorder With Hyperactivity: early-phase trial registry
1 of 21 indexed Attention Deficit Disorder With Hyperactivity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 1 currently recruiting · #797 of 28,707 conditions by registered trial count
Attention Deficit Disorder With Hyperactivity: 21 US clinical trials tracked, 1 recruiting.
Attention Deficit Disorder With Hyperactivity is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Aevi Genomic Medicine, LLC, a Cerecor company, running 2 of these trials.
Enrollment posture brief
Registry condition attention-deficit-disorder-with-hyperactivity
OPEN 1 | RECR 5% | LATE 2 | EARLY 6 | RANK #797 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Recurrent Breast Cancer (5% recruiting · 20 trials)
Attention Deficit Disorder With Hyperactivity lists 1 open slots (5% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Attention Deficit Disorder With Hyperactivity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Attention Deficit Disorder With Hyperactivity is recruiting below its size-band peers.
1 of 21 indexed trials (4.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Attention Deficit Disorder With Hyperactivity trials is spread across many organizations.
Aevi Genomic Medicine, LLC, a Cerecor company accounts for 2 of 21 trials (9.5%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Attention Deficit Disorder With Hyperactivity enrolment sits around 101 participants.
Median target enrolment is 101 among the 21 trials that report a genuine target (sentinel values excluded). 10 of those (47.6%) plan for fewer than 100 participants.
-
Attention Deficit Disorder With Hyperactivity research is mostly interventional.
18 interventional and 3 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Massachusetts General Hospital
NCT05354232
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
National Institute of Mental Health (NIMH)
NCT00001246
School-Based Mental Health Services for Urban Children
University of Illinois at Chicago
NCT00612690
Software Treatment for Actively Reducing Severity of ADHD
Akili Interactive Labs
NCT02674633
Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)
National Institute of Mental Health (NIMH)
NCT00001206
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
Seattle Children's Hospital
NCT00830700
Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001915
Software Treatment for Actively Reducing Severity of ADHD - Follow Up
Akili Interactive Labs
NCT02828644
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
NYU Langone Health
NCT00381407
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Florida International University
NCT00050622
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Tris Pharma
NCT02083783
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Aevi Genomic Medicine, LLC, a Cerecor company
NCT02777931
Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD
Noven Therapeutics
NCT00466791
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
University of Nebraska
NCT00254462
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
Icahn School of Medicine at Mount Sinai
NCT00278473
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
University of California, San Francisco
NCT00071656
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
New River Pharmaceuticals
NCT00248092
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
Aevi Genomic Medicine, LLC, a Cerecor company
NCT03006367
Effects of Exercise Intensity on ADHD Symptoms
Kent State University
NCT06753253
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
The University of Texas Health Science Center, Houston
NCT00178503
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
New York State Psychiatric Institute
NCT00218543
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Attention Deficit Disorder With Hyperactivity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Attention Deficit Disorder With Hyperactivity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Attention Deficit Disorder With Hyperactivity page
21 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Attention Deficit Disorder With Hyperactivity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aevi Genomic Medicine, LLC, a Cerecor company sponsors the most Attention Deficit Disorder With Hyperactivity trials on record, review their full trial history before evaluating a specific study. See Aevi Genomic Medicine, LLC, a Cerecor company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Attention Deficit Disorder With Hyperactivity condition card totals 21 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.